An alkylresorcinol synthase mutant and its application

By directionally modifying alkylresorcinol synthase and mutating the amino acids near its substrate binding pocket, a high-activity enzyme mutant was obtained, which solved the problem of low catalytic efficiency of ARSs and achieved a significant increase in the yield of alkylresorcinol, making it suitable for Escherichia coli microbial synthesis plants.

CN123063370APending Publication Date: 2026-11-10BY HEALTH CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202611463119.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-20
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

The existing alkylresorcinol synthases (ARSs) have low catalytic efficiency, which has become a key bottleneck limiting the production of alkylresorcinol and making it difficult to meet the needs of industrial production.

Method used

By directionally modifying alkylresorcinol synthase and mutating the amino acids near its substrate binding pocket, especially by changing certain amino acid sites to alanine or valine, a highly active enzyme mutant was obtained and efficiently expressed in Escherichia coli.

Benefits of technology

It significantly increased the yield of alkylresorcinol, and the mutant has stronger catalytic ability than the native enzyme, making it suitable for large-scale, green and environmentally friendly microbial synthesis processes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123063370A_ABST
    Figure CN123063370A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of bioenzyme engineering technology, specifically, it relates to an alkylresorcinol synthase mutant and its applications. By mutating amino acid residues near the substrate-binding pocket of the alkylresorcinol synthase, this invention screened several alkylresorcinol synthase mutants that can significantly increase the yield of alkylresorcinol. The alkylresorcinol synthase mutants provided by this invention can efficiently catalyze the synthesis of alkylresorcinol, thereby improving the yield of alkylresorcinol synthesis and providing a new technical solution for the green biomanufacturing of alkylresorcinol, showing promising application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of bioenzyme engineering technology, specifically to an alkylresorcinol synthase mutant and its applications. Background Technology

[0002] Alkylresorcinols (ARs) are a class of phenolic lipid compounds with 1,3-resorcinol as the parent nucleus and alkyl side chains at the 5-position of the benzene ring with an odd number of carbon atoms. They are specifically enriched in the bran of cereal grains such as wheat and rye, and are important active ingredients and markers of cereal bran, accounting for a large proportion of cereal phenolic substances. ARs are abundant in whole grains but almost absent in refined grains. After ingestion, they can be absorbed by the human body and are stably detected in the blood. Therefore, they are often used as dietary biomarkers to evaluate the intake of whole grain foods. my country's grain industry standard "Whole Wheat Flour" (LS / T 3244—2015) has listed the content of alkylresorcinols as an important biomarker indicator for judging the quality of whole wheat flour, and uses it for the identification and quality control of whole wheat flour.

[0003] Antibiotics (ARs) possess various physiological activities, including antioxidant, anti-inflammatory, antibacterial, and neuroprotective effects, and are closely related to reducing the risk of cancers such as colon cancer, prostate cancer, and breast cancer, as well as improving metabolic health. With the improvement of modern living standards, natural, healthy, and green whole grain foods are increasingly favored, and research on grain foods is also increasing. However, most grain foods we consume daily are produced through processing such as grinding, crushing, and baking. This entire refining process affects the content and bioavailability of bioactive substances in whole grain foods. Since ARs mainly come from grain foods, and people's daily diets are mainly composed of refined grain foods, it is difficult to obtain sufficient ARs through diet alone. Therefore, the safe and efficient production of ARs through industrial means has significant practical implications and application prospects.

[0004] Currently, the main industrial production methods for acrylamide (ARs) include plant extraction and microbial fermentation. Plant extraction requires whole grains as raw materials and involves strong acids and alkalis, resulting in environmental pollution, limited raw material sources, and product allergenicity, making it difficult to meet market demands for green and sustainable production methods. With the development of genetic engineering technology, biosynthesis is receiving increasing attention due to its scalability, lower cost, and environmental friendliness, making the safe and efficient production of ARs extremely important and urgent.

[0005] Escherichia coli possesses advantages such as a clear genetic background, a mature and well-developed system of molecular biological manipulation elements, ease of cultivation and control, simple and efficient transformation operations, high protein expression levels, low cost, and short cycle time, making it an ideal host bacterium for heterologous expression of functional enzymes and the construction of microbial cell factories. Alkylresorcinol synthase (ARSs) belongs to the type III polyketide synthase family. Starting with a specific acyl-CoA, it catalyzes three decarboxylation condensations of three molecules of malonyl-CoA via a cyclization mechanism, followed by an aldol condensation at C2 and C7 to form the product, alkylresorcinol. By introducing the gene encoding ARSs into the strain, the microbial synthesis of alkylresorcinol can be achieved.

[0006] However, existing research indicates that ARSs have relatively low catalytic efficiency, which has become a key bottleneck limiting the yield of alkylresorcinol. Targeted enzyme modification and fermentation screening are commonly used methods to obtain superior enzyme mutants. Targeted modification and screening of ARSs not only helps to explore their catalytic mechanisms in greater depth but also has significant implications for further modifying enzyme molecules, improving the ability of *E. coli* to produce alkylresorcinol, and expanding their applications in fermentation production. Therefore, developing ARS variants with higher catalytic efficiency and superior performance and achieving their efficient expression in microbial cell factories is a pressing technical problem that needs to be solved in this field. Summary of the Invention

[0007] To address the problem of insufficient enzyme activity and low catalytic efficiency of existing alkylresorcinol synthases (ARSs), the inventors conducted extensive and long-term research, performing various mutations and screenings on alkylresorcinol synthases, and finally obtained a high-activity enzyme mutant, thus completing this invention.

[0008] In a first aspect, the present invention provides an alkylresorcinol synthase mutant, wherein the alkylresorcinol synthase mutant is a mutation occurring near the substrate binding pocket of the alkylresorcinol synthase.

[0009] In one embodiment, the mutation comprises any one or a combination of the following mutations 1-2: Mutation 1: Some amino acids within the 5 Å pocket of the alkylresorcinol synthase substrate structure are mutated to alanine (Ala), which has less steric hindrance; Mutation 2: Some amino acids located within the 5 Å pocket of the alkylresorcinol synthase substrate structure are mutated to the more hydrophobic valine (Val).

[0010] Preferably, in this invention, the alkylresorcinol synthase has the nucleotide sequence shown in SEQ ID NO. 1.

[0011] In a second aspect, the present invention provides an alkylresorcinol synthase mutant, wherein the alkylresorcinol synthase mutant is characterized by a mutation in amino acid residues near the substrate binding pocket of the alkylresorcinol synthase, and the amino acid sequence of the alkylresorcinol synthase is shown in SEQ ID NO. 2.

[0012] Preferably, the mutation of the alkylresorcinol synthase mutant satisfies at least one of the following conditions: In mutation 1, amino acids at positions 38, 41, 42, 45, 179, 180, 183, 187, 221, 235, 236, 238, 239, 272, 273, 274, 275, and 276 of the amino acid sequence of alkylresorcinol synthase are mutated, with any one of these sites being mutated to alanine; In mutation 2, amino acids at positions 38, 42, 179, L180, 183, 187, 221, 235, 238, 239, and 273 of the amino acid sequence of alkylresorcinol synthase are mutated, with any one of these sites mutating to valine. Preferably, the alkylresorcinol synthase mutant of the present invention comprises a combination of the above-mentioned mutation 1 and mutation 2.

[0013] In one embodiment, the alkylresorcinol synthase mutation 1 includes any one or a combination of I38, K41, I42, H45, L179, L180, L183, L187, I221, S235, V236, L238, P239, G272, G273, E274, R275, and V276.

[0014] In one embodiment, the alkylresorcinol synthase mutant 2 includes any one or a combination of I38, I42, L179, L180, L183, L187, I221, S235, L238, P239, and G273.

[0015] In one embodiment, the alkylresorcinol synthase mutant is mutated to one or more of I38, L183A, S235A, L179V, I221V, and S235V.

[0016] In one embodiment, the alkylresorcinol synthase mutant is mutated to one or more of I38A / I221V, L183A / S235V, S235A / L179V, and S235A / I221V.

[0017] In this invention, although the aforementioned alkylresorcinol synthase mutant has undergone mutations at one or several amino acid sites, it still retains the basic functions of alkylresorcinol synthase, and its catalytic synthesis ability is even stronger than that of the native synthase.

[0018] In a third aspect, the present invention provides a nucleic acid molecule comprising a nucleotide sequence encoding the alkylresorcinol synthase mutant described in the first aspect of the present invention.

[0019] In a fourth aspect, the present invention provides an expression vector containing the nucleic acid molecule described in the third aspect of the present invention.

[0020] In one embodiment, the expression vector is a plasmid vector.

[0021] In a fifth aspect, the present invention provides a genetically engineered bacterium containing the expression vector described in the fourth aspect of the present invention. The substrate bacteria of the genetically engineered bacterium are one of *Escherichia coli*, *Corynebacterium glutamicum*, and *Bacillus subtilis*.

[0022] In one embodiment, the chassis bacteria are Escherichia coli, and the Escherichia coli strains include BL21, C41, OrigamB, Rosetta, Turner, JM109, HMS174, NovaBlue, AD494, Origami, and Nissle 1917.

[0023] Preferably, the chassis bacteria used in this invention are Escherichia coli Nissle 1917, which does not contain pathogenic factors such as enterotoxins, hemolytic toxins and cytotoxins, and poses no safety risk to the host.

[0024] In one embodiment, the *E. coli* Nissle 1917 is a genetically modified *E. coli* Nissle 1917, the modification including integrating a specific sequence of T7 RNA polymerase expression cassette at a specific site in the Nissle 1917 strain, deleting the cryptic plasmid, and knocking out two other interfering genes on the genome. endA Genes and ompT Genes; for specific methods of modification, see CN202310516515.6.

[0025] In a sixth aspect, the present invention provides a method for producing alkylresorcinol, wherein the method uses the aforementioned alkylresorcinol synthase mutant of the present invention as a catalyst to catalyze the production of alkylresorcinol from ester acyl-CoA.

[0026] Beneficial effects This invention obtained several aminoalkylresorcinol synthase mutants through mutation and screening, particularly three genetically engineered bacteria containing the I38A, L183A, and S235A mutations, which significantly improved the yield of alkylresorcinol during fermentation. The technical solution of this invention lays the foundation for further metabolic engineering of *E. coli* to produce alkylresorcinol. The recombinant *E. coli* construction method provided by this invention is simple, easy to use, and has excellent application prospects. Attached Figure Description

[0027] Figure 1 :C 15: 0 C 17: 0 C 19: 0 C 21: 0 C 25: 0 Liquid chromatography-mass spectra of mixed standards and fermentation samples, where (A) represents C. 15: 0 C 17: 0 C 19: 0 C 21: 0 C 25: 0 Liquid chromatography-mass spectra of mixed standards; (B) is TCBJ117- SlPKS2 Liquid chromatography-mass spectrometry (LC-MS) peaks of the fermentation broth.

[0028] Figure 2 HPLC chromatograms of alkyl resorcinol synthase, (A) represents the HPLC results of the standard; (B) represents the HPLC results of the ARs sample.

[0029] Figure 3 Alkyl resorcinol synthase CbARSs Key sites for substrate-binding pocket mutations.

[0030] Figure 4 Alkyl resorcinol synthase CbARSs And the yield of shake-flask fermentation of double mutant engineered strains. Detailed Implementation

[0031] To further illustrate the technical means and effects of the present invention, the following describes the technical solution of the present invention in conjunction with preferred embodiments of the present invention. However, the present invention is not limited to the scope of the embodiments.

[0032] Unless otherwise specified in the examples, the procedures should be performed under standard conditions, manufacturer's recommendations, or relevant operating instructions. The molecular biology and bioinformatics methods used in the examples can be found in relevant textbooks, reference books, and educational websites, including but not limited to "Molecular Biology," "Genetic Engineering," "Molecular Cloning: A Laboratory Manual," and "A Concise Guide to Molecular Biology Experiments." Reagents or instruments whose manufacturers are not specified are all commercially available standard products.

[0033] Example 1: Construction of chassis strains and discovery of alkyl resorcinol synthase 1.1 Probiotic Escherichia coli EcNc Δ attB (lacUV5-T7) ΔendAΔOmpT Chassis preparation According to the method described in patent number CN 202310516515.6, in the original strain of probiotic Escherichia coli Nissle1917, an optimized T7 RNAP expression cassette is inserted into the Nissle 1917 genome using gene editing technology. The insertion site of the expression cassette is on the genome. attB Sites, then knocked out endA and ompT Gene, preparation of EcNc Δ attB (lacUV5-T7) ΔendAΔompT It was named "TCBJ117".

[0034] 1.2 Discovery of Alkyl Resorcinol Synthesizers (ARSs) alkyl resorcinol synthase with known functional activity Sporotrichum laxum ATCC 15155 source Sl-PKS2 Genes as templates ( Sl-PKS2 Using the GeneBanK accession number KU560627, three-dimensional structures were constructed from protein sequences in a potential functional protein database to obtain structural models of the protein sequences. These structural models were then compared with known... Sl-PKS2 The structure is TM-aligned to obtain the result. Sl-PKS2 High conformational similarity to enzyme activity predicts proteins Candidatus Brocadia fulgida The source gene was named CbARSs . CbARSs The gene nucleotide sequence is shown in SEQ ID NO.1, and the amino acid sequence is shown in SEQ ID NO.2.

[0035] For testing CbARSs Gene activity was optimized by artificially synthesized codons commissioned to Wuhan Tianyi Huayu Gene Technology Co., Ltd. Sl-PKS2 and CbARSs The gene was synthesized and an expression vector was constructed. After being transformed into the chassis strain TCBJ117, the alkyl resorcinol yield of the engineered strain was tested. Specifically, the synthesized gene fragment was ligated into the vector pRSFDuet using a homologous recombination kit (ProLigation-Free Cloning Kit, abm Inc., catalog number E086), resulting in the recombinant plasmid pRSFDuet- Sl-PKS2 pRSFDuet-CbARSs The recombinant plasmids were transformed into the chassis strain TCBJ117 to obtain the engineered strain TCBJ117- Sl-PKS2 (Positive control), TCBJ117- CbARSs The empty plasmid vector pRSFDuet was transformed into TCBJ117 as a negative control strain, TCBJ117-CK.

[0036] Example 2: Screening and Fermentation Detection of Alkyl Resorcinol Synthases (ARSs) Expression The engineered strain TCBJ117- Sl-PKS2 TCBJ117- CbARSs Single colonies of both the strain and the negative control strain TCBJ117-CK were picked and inoculated into LB medium (5 g / L yeast extract, 10 g / L tryptone, 10 g / L NaCl) containing 50 μg / mL kanamycin, and cultured overnight at 37 ℃ and 200 rpm for 12 h. The seed culture was then transferred at 1% to 100 mL of fresh LB medium (containing 50 μg / mL kanamycin) and cultured at 37 ℃ and 200 rpm until the bacterial growth rate reached OD. 600 = 0.6, add 0.3 mM IPTG to induce expression, ferment at 30 ℃ and 200 rpm for 24 h.

[0037] Collect the fermentation broth, centrifuge at 6000 rpm for 10 min, and separate the supernatant and precipitate. Add 100 mL of ethyl acetate to the supernatant, and extract by shaking at 150 rpm for 12 h, collecting the ethyl acetate layer. Add 10 mL of PBS buffer to the precipitate, sonicate for 15 min, centrifuge the cell lysate at 12000 rpm for 10 min, take the supernatant, add 100 mL of ethyl acetate, and extract by shaking at 150 rpm for 12 h, collecting the ethyl acetate layer. Mix the two batches of ethyl acetate solutions obtained from extraction, dry under vacuum by rotary evaporation, dissolve and resuspend the solid in 2 mL of methanol, filter through a 0.22 μm filter membrane, and use for liquid chromatography-mass spectrometry (LC-MS) analysis with 5-pentadecanylresorcinol (C5000). 15:0 ), 5-heptadecyl isophthalic acid (C 17:0 ), 5-Ninedecylresorcinol (C 19:0 ) and 5-tetradecylresorcinol (C 25:0 The standard sample is used as a test marker.

[0038] The expressed product was detected by liquid chromatography and mass spectrometry. The liquid chromatography detection conditions for alkyl resorcinol were as follows: (1) Instrument: Agilent 1200 HPLC instrument; (2) Chromatographic column: Agilent Eclipse Plus C 18, 5 μm, 4.6 mm × 250 mm; (3) Column temperature: 30 ℃; (4) Mobile phase: Mobile phase A: 89% (v / v) methanol aqueous solution and mobile phase B: 99% (v / v) methanol aqueous solution; (5) Flow rate: 0.65 mL / min; (6) Elution gradient: see Table 1; (7) Detection wavelength: 280 nm.

[0039] Table 1. Elution gradient of alkylresorcinol in liquid chromatography.

[0040] MS detection conditions: (1) Ionization method: Electrospray negative ion mode; (2) Testing method: Product Ion; (3) Atomizing gas pressure: 40 psi; (4) Ion spray voltage: 4000 V; (5) Dryer temperature: 350 ℃; (6) Drying airflow rate: 8 L / min.

[0041] (7) Qualitative ion pairs, fragmentation voltage and collision energy are shown in Table 2.

[0042] Table 2

[0043] Test results are shown Figure 1 , Figure 2 Alkyl resorcinol synthase CbARSs Consistent with the detection products of the reference gene Sl-PKS2, 5-pentadecanylresorcinol (C10-5-phenylenevinylhydroquinone) was detected in both. 15:0 ), 5-Heptadecanylresorcinol (C 17:0 ), 5-Ninedecylresorcinol (C 19:0 ), and the product 5-tetradecylresorcinol (C) was not detected in either of them. 25:0 ).

[0044] The yields of alkyl resorcinol synthases (ARSs) are shown in Table 3, TCBJ117- CbARSs The yield of the engineered bacteria was higher than that of the positive control engineered bacteria TCBJ117- Sl-PKS2 The output of TCBJ117- CbARSs The yield of the engineered bacteria was 29.28 mg / L, which was 30.4% higher than that of the positive control strain.

[0045] Table 3. Yield of alkyl resorcinol

[0046] Example 3: Determination of mutation sites and fermentation yield of alkyl resorcinol synthases (ARSs) 3.1 Screening for mutation sites in alkyl resorcinol synthases (ARSs) The catalytic mechanism of ARSs follows an ordered reaction mechanism, employing a cyclization mechanism to generate alkylresorcinol from malonyl-CoA and fatty acyl-CoA starting units. ARSs catalyze a three-stage decarboxylation condensation of three molecules of malonyl-CoA using a specific acyl-CoA substrate, followed by an aldol condensation at C2 and C7 to form the product. To obtain a highly efficient alkylresorcinol mutant using malonyl-CoA and fatty acyl-CoA as substrates, the one obtained in Example 1 was used. CbARSs Starting from genes, this study integrates multi-scale computational biology methods such as homology modeling, molecular docking, conservation analysis, molecular dynamics simulation, and model prediction to pinpoint key amino acid residues within a 5 Å range of the substrate binding pocket. Figure 3 ), 29 mutation sites were designed (see Table 4), of which M1-M18 are mainly targeted at the substrate binding pocket and mutated to alanine; M19-M29 are mainly targeted at increasing the hydrophobicity of the substrate binding pocket and mutated to valine.

[0047] Alanine scanning was performed based on the dynamic trajectory and evolutionary conservation patterns of the alanine nucleus to screen for potential beneficial mutation sites. The following 18 key sites were selected for mutation to alanine: I38, K41, I42, H45, L179, L180, L183, L187, I221, S235, V236, L238, P239, G272, G273, E274, R275, and V276. Valine scanning was also performed based on the dynamic trajectory and evolutionary conservation patterns to screen for potential beneficial mutation sites. The following 16 key sites were selected for mutation to valine: I38, I42, L179, L180, L183, L187, I221, S235, L238, P239, and G273. This was to test... CbARSs The activity of mutant genes, CbARSs The amino acid sequences of the mutant genes were optimized and synthesized by Wuhan Tianyi Huayu Gene Technology Co., Ltd., and the mutants were named as shown in Table 4.

[0048] Table 4 Substrate-binding pocket single mutants

[0049] 3.2 CbARSs Construction of genetically engineered strains with single mutants at the substrate binding pocket and determination of fermentation yield The single mutant gene obtained above was ligated into the vector pRSFDuet, and then electroporated into TCBJ117 to obtain a genetically engineered strain containing the mutant. Simultaneously, the engineered strain TCBJ117- CbARSs As a control strain (WT), the fermentation process and detection methods were the same as in Example 2.

[0050] The results are shown in Table 5. A total of six positive mutants with significantly increased AR yield were obtained. Among the 18 alanine mutants (M1-M18), three positive mutants with significantly increased AR yield were obtained: M1, M7, and M10. Specifically, the mutations were: isoleucine at position 38 to alanine (I38A), leucine at position 183 to alanine (L183A), and serine at position 235 to alanine (S235A). After 24 h of fermentation, the yield of M1 (I38A) reached 31.6 mg / L, an increase of 7.9% compared to the control strain; the yield of M7 (L183A) reached 32.84 mg / L, an increase of 12.15% compared to the control strain; and the yield of M10 (S235A) reached 37.7 mg / L, an increase of 28.75% compared to the control strain.

[0051] Among the 11 mutants of valine (M19-M29), three positive mutants, M21, M25, and M26, were obtained that significantly increased AR yield. After 24 h of fermentation, the yield of M21 (L179V) reached 34.1 mg / L, an increase of 16.46% compared with the control strain; the yield of M25 (I221V) reached 32.7 mg / L, an increase of 11.68% compared with the control strain; and the yield of M26 (S235V) reached 36.2 mg / L, an increase of 23.63% compared with the control strain.

[0052] Table 5. Yields of alkylresorcinol synthase mutants (ARs)

[0053] Example 4: CbARSs Screening of genetically engineered bacteria with double mutants at the substrate binding pocket 4.1 Construction of double mutant plasmids at the substrate binding pocket Based on the results of Example 3, positive mutants M1, M7, M10, M21, M25, and M26 were combined to obtain mutants with expanded substrate binding pockets and enhanced hydrophobicity, thereby further improving catalytic efficiency and yielding yield-enhancing dual-site mutants. The relevant dual-mutation sites are shown in Table 6. The eight combinations are I38A / L179V, I38A / I221V, I38A / S235V, L183A / L179V, L183A / I221V, L183A / S235V, S235A / L179V, and S235A / I221V.

[0054] Specifically: using plasmid pRSFDuet- containing a single mutation site. CbARSs (I38A) pRSFDuet- CbARSs (L183A) pRSFDuet- CbARSs (S235A) Using a template, upstream and downstream primers for the second mutation site were designed. Details of the upstream and downstream primers are shown in Table 7. Full plasmid PCR amplification was performed using the following PCR program (95℃ 30s; 98℃ 20s, 55℃ 20s, 72℃ 1min, 30 cycles; 72℃ 4min, 16℃ incubation). The amplified plasmid was transformed into *E. coli* DH5α. Single colonies were picked from resistant plates, screened, and sequenced. Correct sequencing confirmed the successful acquisition of pRSFDuet- containing the double mutation site. CbARSs (I38A-L179V) pRSFDuet- CbARSs (I38A-I221V) pRSFDuet- CbARSs (I38A-S235V) pRSFDuet- CbARSs (L183A-L179V) pRSFDuet- CbARSs (L183A-I221V) pRSFDuet- CbARSs (L183A-S235V) pRSFDuet- CbARSs (S235A-L179V) pRSFDuet- CbARSs (S235A-I221V) Engineered bacteria. Plasmids were extracted from the above 8 engineered bacteria using a plasmid extraction kit to obtain recombinant plasmids containing a double mutation in the alkylresorcinol synthase gene sequence.

[0055] Table 6: Double mutants at the substrate binding pocket

[0056] Table 7: Upstream and downstream primers for the second site of the mutant

[0057] 4.2 Construction and fermentation yield determination of double mutant genetically engineered bacteria at the substrate binding pocket The above double mutant plasmid pRSFDuet- CbARSs (I38A-L179V) pRSFDuet- CbARSs (I38A-I221V) pRSFDuet- CbARSs (I38A-S235V) pRSFDuet- CbARSs (L183A-L179V) pRSFDuet- CbARSs (L183A-I221V) pRSFDuet- CbARSs (L183A-S235V) pRSFDuet- CbARSs (S235A-L179V) pRSFDuet- CbARSs (S235A-I221V) The mutant-containing genetically engineered strain was obtained by electroporation into TCBJ117. Simultaneously, the engineered strain TCBJ117- CbARSs As a control strain (WT), the fermentation process and detection methods were the same as in Example 2.

[0058] The specific results are shown in Table 8. Figure 4 Among the eight mutant combinations of M30-M37, four mutant combinations M31, M35, M36, and M37 showed a significant increase in yield compared to the control group (WT). Among them, the mutant M37, which had the best substrate binding pocket, had the highest yield of 59.32 mg / L, which was 102.59% higher than the yield of the positive control strain.

[0059] Table 8 Yields of Combined Mutants

[0060] The embodiments described above are merely illustrative of several implementations of the present invention, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the invention patent. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these all fall within the protection scope of the present invention. Therefore, the protection scope of this invention patent should be determined by the appended claims.

Claims

1. An alkylresorcinol synthase mutant, characterized in that, The alkylresorcinol synthase mutant is a mutation of amino acid residues near the substrate binding pocket of the alkylresorcinol synthase, and the amino acid sequence of the alkylresorcinol synthase is shown in SEQ ID NO.

2.

2. The mutant according to claim 1, characterized in that, The mutation includes any one or a combination of the following mutations 1-2: Mutation 1: Some amino acids within the 5 Å range of the substrate binding pocket of alkylresorcinol synthase are mutated to alanine (Ala), which has less steric hindrance; Mutation 2: Some amino acids located within the 5 Å range of the substrate binding pocket of alkylresorcinol synthase are mutated to the more hydrophobic valine (Val).

3. An alkylresorcinol synthase mutant, characterized in that, The mutation of the alkylresorcinol synthase mutant satisfies at least one of the following conditions: (1) In mutation 1, the amino acids at positions 38, 41, 42, 45, 179, 180, 183, 187, 221, 235, 236, 238, 239, 272, 273, 274, 275, and 276 of the amino acid sequence of alkylresorcinol synthase are mutated, and any one of these sites is mutated to alanine; (2) In mutation 2, the amino acids at positions 38, 42, 179, L180, 183, 187, 221, 235, 238, 239, and 273 of the amino acid sequence of alkylresorcinol synthase are mutated, and any one of these sites is mutated to valine. The amino acid sequence of the alkylresorcinol synthase is shown in SEQ ID NO.

2.

4. The mutant according to claim 3, characterized in that, The mutation of the alkylresorcinol synthase mutant is any combination of mutation 1 and mutation 2.

5. An alkylresorcinol synthase mutant, characterized in that, The mutation of the alkylresorcinol synthase mutant is any one of the following ①-②: ①: One or more of I38A, L183A, S235A, L179V, I221V, and S235V; ②: One or more of I38A / I221V, L183A / S235V, S235A / L179V, and S235A / I221V.

6. A nucleic acid molecule, characterized in that, The nucleic acid molecule includes a nucleotide sequence encoding an alkylresorcinol synthase mutant according to any one of claims 1-5.

7. An expression carrier, characterized in that, The expression vector contains the nucleic acid molecule as described in claim 6; preferably, the expression vector is a plasmid vector.

8. A genetically engineered bacterium, characterized in that, The genetically engineered bacteria contain the expression vector described in claim 7.

9. The genetically engineered bacterium according to claim 8, characterized in that, The chassis bacteria of the genetically engineered bacteria are one of Escherichia coli, Corynebacterium glutamicum, and Bacillus subtilis.

10. A method for producing alkylresorcinol, characterized in that, The method uses the alkylresorcinol synthase mutant of any one of claims 1-5 as a catalyst to catalyze the synthesis of alkylresorcinol.

Citation Information

Patent Citations

  • T7 expression system-based Nissel 1917 engineering bacterium as well as preparation method and application of T7 expression system-based Nissel 1917 engineering bacterium

    CN118931930A